Cargando…
Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models
To develop a vaccine candidate against coronavirus disease 2019 (COVID-19), we generated a lentiviral vector (LV) eliciting neutralizing antibodies against the Spike glycoprotein of SARS-CoV-2. Systemic vaccination by this vector in mice, in which the expression of the SARS-CoV-2 receptor hACE2 has...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738935/ https://www.ncbi.nlm.nih.gov/pubmed/33357418 http://dx.doi.org/10.1016/j.chom.2020.12.010 |
_version_ | 1783623225424478208 |
---|---|
author | Ku, Min-Wen Bourgine, Maryline Authié, Pierre Lopez, Jodie Nemirov, Kirill Moncoq, Fanny Noirat, Amandine Vesin, Benjamin Nevo, Fabien Blanc, Catherine Souque, Philippe Tabbal, Houda Simon, Emeline Hardy, David Le Dudal, Marine Guinet, Françoise Fiette, Laurence Mouquet, Hugo Anna, François Martin, Annette Escriou, Nicolas Majlessi, Laleh Charneau, Pierre |
author_facet | Ku, Min-Wen Bourgine, Maryline Authié, Pierre Lopez, Jodie Nemirov, Kirill Moncoq, Fanny Noirat, Amandine Vesin, Benjamin Nevo, Fabien Blanc, Catherine Souque, Philippe Tabbal, Houda Simon, Emeline Hardy, David Le Dudal, Marine Guinet, Françoise Fiette, Laurence Mouquet, Hugo Anna, François Martin, Annette Escriou, Nicolas Majlessi, Laleh Charneau, Pierre |
author_sort | Ku, Min-Wen |
collection | PubMed |
description | To develop a vaccine candidate against coronavirus disease 2019 (COVID-19), we generated a lentiviral vector (LV) eliciting neutralizing antibodies against the Spike glycoprotein of SARS-CoV-2. Systemic vaccination by this vector in mice, in which the expression of the SARS-CoV-2 receptor hACE2 has been induced by transduction of respiratory tract cells by an adenoviral vector, confers only partial protection despite high levels of serum neutralizing activity. However, eliciting an immune response in the respiratory tract through an intranasal boost results in a >3 log(10) decrease in the lung viral loads and reduces local inflammation. Moreover, both integrative and non-integrative LV platforms display strong vaccine efficacy and inhibit lung deleterious injury in golden hamsters, which are naturally permissive to SARS-CoV-2 replication and closely mirror human COVID-19 physiopathology. Our results provide evidence of marked prophylactic effects of LV-based vaccination against SARS-CoV-2 and designate intranasal immunization as a powerful approach against COVID-19. |
format | Online Article Text |
id | pubmed-7738935 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77389352020-12-16 Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models Ku, Min-Wen Bourgine, Maryline Authié, Pierre Lopez, Jodie Nemirov, Kirill Moncoq, Fanny Noirat, Amandine Vesin, Benjamin Nevo, Fabien Blanc, Catherine Souque, Philippe Tabbal, Houda Simon, Emeline Hardy, David Le Dudal, Marine Guinet, Françoise Fiette, Laurence Mouquet, Hugo Anna, François Martin, Annette Escriou, Nicolas Majlessi, Laleh Charneau, Pierre Cell Host Microbe Article To develop a vaccine candidate against coronavirus disease 2019 (COVID-19), we generated a lentiviral vector (LV) eliciting neutralizing antibodies against the Spike glycoprotein of SARS-CoV-2. Systemic vaccination by this vector in mice, in which the expression of the SARS-CoV-2 receptor hACE2 has been induced by transduction of respiratory tract cells by an adenoviral vector, confers only partial protection despite high levels of serum neutralizing activity. However, eliciting an immune response in the respiratory tract through an intranasal boost results in a >3 log(10) decrease in the lung viral loads and reduces local inflammation. Moreover, both integrative and non-integrative LV platforms display strong vaccine efficacy and inhibit lung deleterious injury in golden hamsters, which are naturally permissive to SARS-CoV-2 replication and closely mirror human COVID-19 physiopathology. Our results provide evidence of marked prophylactic effects of LV-based vaccination against SARS-CoV-2 and designate intranasal immunization as a powerful approach against COVID-19. Elsevier Inc. 2021-02-10 2020-12-16 /pmc/articles/PMC7738935/ /pubmed/33357418 http://dx.doi.org/10.1016/j.chom.2020.12.010 Text en © 2020 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Ku, Min-Wen Bourgine, Maryline Authié, Pierre Lopez, Jodie Nemirov, Kirill Moncoq, Fanny Noirat, Amandine Vesin, Benjamin Nevo, Fabien Blanc, Catherine Souque, Philippe Tabbal, Houda Simon, Emeline Hardy, David Le Dudal, Marine Guinet, Françoise Fiette, Laurence Mouquet, Hugo Anna, François Martin, Annette Escriou, Nicolas Majlessi, Laleh Charneau, Pierre Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models |
title | Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models |
title_full | Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models |
title_fullStr | Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models |
title_full_unstemmed | Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models |
title_short | Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models |
title_sort | intranasal vaccination with a lentiviral vector protects against sars-cov-2 in preclinical animal models |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738935/ https://www.ncbi.nlm.nih.gov/pubmed/33357418 http://dx.doi.org/10.1016/j.chom.2020.12.010 |
work_keys_str_mv | AT kuminwen intranasalvaccinationwithalentiviralvectorprotectsagainstsarscov2inpreclinicalanimalmodels AT bourginemaryline intranasalvaccinationwithalentiviralvectorprotectsagainstsarscov2inpreclinicalanimalmodels AT authiepierre intranasalvaccinationwithalentiviralvectorprotectsagainstsarscov2inpreclinicalanimalmodels AT lopezjodie intranasalvaccinationwithalentiviralvectorprotectsagainstsarscov2inpreclinicalanimalmodels AT nemirovkirill intranasalvaccinationwithalentiviralvectorprotectsagainstsarscov2inpreclinicalanimalmodels AT moncoqfanny intranasalvaccinationwithalentiviralvectorprotectsagainstsarscov2inpreclinicalanimalmodels AT noiratamandine intranasalvaccinationwithalentiviralvectorprotectsagainstsarscov2inpreclinicalanimalmodels AT vesinbenjamin intranasalvaccinationwithalentiviralvectorprotectsagainstsarscov2inpreclinicalanimalmodels AT nevofabien intranasalvaccinationwithalentiviralvectorprotectsagainstsarscov2inpreclinicalanimalmodels AT blanccatherine intranasalvaccinationwithalentiviralvectorprotectsagainstsarscov2inpreclinicalanimalmodels AT souquephilippe intranasalvaccinationwithalentiviralvectorprotectsagainstsarscov2inpreclinicalanimalmodels AT tabbalhouda intranasalvaccinationwithalentiviralvectorprotectsagainstsarscov2inpreclinicalanimalmodels AT simonemeline intranasalvaccinationwithalentiviralvectorprotectsagainstsarscov2inpreclinicalanimalmodels AT hardydavid intranasalvaccinationwithalentiviralvectorprotectsagainstsarscov2inpreclinicalanimalmodels AT ledudalmarine intranasalvaccinationwithalentiviralvectorprotectsagainstsarscov2inpreclinicalanimalmodels AT guinetfrancoise intranasalvaccinationwithalentiviralvectorprotectsagainstsarscov2inpreclinicalanimalmodels AT fiettelaurence intranasalvaccinationwithalentiviralvectorprotectsagainstsarscov2inpreclinicalanimalmodels AT mouquethugo intranasalvaccinationwithalentiviralvectorprotectsagainstsarscov2inpreclinicalanimalmodels AT annafrancois intranasalvaccinationwithalentiviralvectorprotectsagainstsarscov2inpreclinicalanimalmodels AT martinannette intranasalvaccinationwithalentiviralvectorprotectsagainstsarscov2inpreclinicalanimalmodels AT escriounicolas intranasalvaccinationwithalentiviralvectorprotectsagainstsarscov2inpreclinicalanimalmodels AT majlessilaleh intranasalvaccinationwithalentiviralvectorprotectsagainstsarscov2inpreclinicalanimalmodels AT charneaupierre intranasalvaccinationwithalentiviralvectorprotectsagainstsarscov2inpreclinicalanimalmodels |